Lophius Biosciences Closes Additional Financing Round with Current Investors Totaling 1.4 Million EUR
Advertisement
Lophius Biosciences announced closing of an additional financing round totaling 1.4 million EUR. All current financial investors, such as S-Refit, High-Tech Gründerfonds (HTGF) as well as Bayernkapital participated in this financing round. The funds will be used for the market introduction of the T-Track© CMV/EBV tests in the field of transplantation, for further development of a diagnostic test for the differential diagnosis of tuberculosis, as well as for the new development of a novel, blood-based multiple sclerosis test.
“We are very pleased to have been able to conclude this financing round with our existing investors in such a short time. Subsequent to the successful establishment of the company over the past year and the imminent conclusion of the test developments for our patented T-Track © CMV/EBV Tests, these new financial resources allow us to prepare for market entry of these tests from the beginning of 2012 with an effective team. Beyond this, we will now intensify the development of additional innovative diagnostic tests based on our patented technology platforms,” said Dr. Michael Lutz, CEO of Lophius Biosciences.
“With the aid of the financing round in the precious year Lophius Biosciences has been able to develop from an essentially academic research company into a small, highly innovative and fully integrated diagnostic company within a very short timeframe. We are absolutely convinced that the Lophius’ technologies and the products have a great potential to provide patients with large diagnostic benefits in our disease areas,” amended Bertram Gilka-Bötzow of S-Refit, Lophius Biosciences’ lead investor.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Last viewed contents
Transition Therapeutics Acquires Exclusive License to GLP-1 for Type I Diabetes Patent Portfolio
Sequenom and NAFTNet to Conduct Fetal Rhesus D Study in Collaboration with Baylor College of Medicine
LFE Laboratorium für industrielle Forschung GmbH & Co. Entwicklungs KG - Bruchköbel, Germany
Andromeda Biotech Successfully Completes Patient Recruitment in Phase III Trials for DiaPep277 for Type 1 Diabetes
Bonnie Bassler and Martin Wikelski receive Max Planck Research Award - Scientists honoured for their pioneering research into the sensory perception of organisms
Stora Enso and Gasum to make renewable energy from wastewater in Sweden
LDC and HZI enter partnership for the discovery of new drugs against multi-resistant bacteria
New model could revolutionise the treatment of autoimmune disease as well as vaccine development - Paradigm shift in immunology: 'Adaptive Tolerance' balances autoimmune reaction
Generex Biotechnology and Pevion Biotech announce plans for immunotherapeutic vaccine collaboration
Successful Outcome from European Clinical Pharmacokinetic Study Comparing SUBA-Itraconazole with Sporanox - HalcyGen to begin Marketing Authorisation Application for Regulators in Europe
